EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

“Time is of the essence”: physician challenges impact patient access to chimeric antigen receptor T-cell therapy

Haley Newman, Anna Sparrow, Kerry Coughlin, Melissa P Beauchamin, Kira Bona, Lucy Cain, Amanda Dinofia, Stephen Grupp, Colleen Kelly, Shannon Maude, Regina Myers, Susan K Parsons und 5 weitere

JNCI Cancer Spectrum · 18.11.2026

DOI: 10.1093/jncics/pkag123 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JNCI Cancer Spectrum, online erschienen am 18.11.2026. Verfasst von Haley Newman und 16 weiteren Autor:innen. Beteiligte Einrichtung: Division of Oncology and Center for Childhood Cancer Research, Children's Hospital of Philadelphia; Philadelphia, PA, USA. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

CD19-directed chimeric antigen receptor T-cell therapy (CART) is a life-saving regimen for children with relapsed/refractory (r/r) B-cell acute lymphoblastic leukemia (B-ALL), yet children from lower socioeconomic and historically marginalized backgrounds are less likely to receive it. Understanding the provider experience of CART referral and post-CART clinical management is critical for designing effective interventions to improve access.

Objective

To explore physicians’ experiences identifying and referring pediatric patients with r/r B-ALL for CART across diverse hospital settings, and to identify physician-perceived facilitators and barriers to CART treatment. Study Design Focus groups using a semi-structured guide were conducted with pediatric oncology physicians, recruited via email and at a national conference, with targeted recruitment of National Cancer Institute Community Oncology Research Program (NCORP) site providers. Questions explored identifying pediatric patients with r/r B-ALL as CART candidates, referring them for CART, and accessing institutional infrastructure to support referral.

Results

Analysis revealed six domains spanning referral to CART and subsequent CART treatment: identification of potentially eligible patients; complexity of CART referral; barriers to insurance approval; physician perception of patients’ social/financial circumstances; and variability in pre- and post-CART management guidelines. Health system-level facilitators and barriers included patient identification and referral processes to tertiary care centers, guidelines for bridging therapy and post-CART toxicity management, and navigation support for patient care and insurance approval.

Conclusion

Findings highlight challenges in community-based settings where resources, infrastructure and geographic availability for CART are variable. Standardizing referral pathways, centralizing trial information, and streamlining CART-center intake process and communication are of immediate importance.

Schlagwörter

Stichwörter der Autor:innen

Immunotherapyaccess to carepediatric oncologyprecision medicine

Autor:innen und Institutionen

  • Division of Oncology and Center for Childhood Cancer Research, Children's Hospital of Philadelphia; Philadelphia, PA, USA.
  • Department of Pediatrics, University of Pennsylvania Perelman School of Medicine; Philadelphia, PA, USA.
  • Penn Center for Cancer Care Innovation (PC3I), University of Pennsylvania; Philadelphia, PA, USA.
  • School of Nursing, Columbia University Irving Medical Center; New York, NY, USA.
  • Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center; New York, NY, USA.
  • Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Harvard Medical School; Boston, MA, USA.

Zitieren

APA

Newman, H., Sparrow, A., Coughlin, K., Beauchamin, M. P., Bona, K., Cain, L., Dinofia, A., Grupp, S., Kelly, C., Maude, S., Myers, R., Parsons, S. K., Rheingold, S. R., Tasian, S. K., White, C., Zheng, D. J., & Leahy, A. B. (2026). “Time is of the essence”: physician challenges impact patient access to chimeric antigen receptor T-cell therapy. JNCI Cancer Spectrum. https://doi.org/10.1093/jncics/pkag123

Vancouver

Newman H, Sparrow A, Coughlin K, Beauchamin MP, Bona K, Cain L, et al. “Time is of the essence”: physician challenges impact patient access to chimeric antigen receptor T-cell therapy. JNCI Cancer Spectrum. 2026. doi:10.1093/jncics/pkag123

BibTeX
@article{Newman2026,
  author = {Newman, Haley and Sparrow, Anna and Coughlin, Kerry and Beauchamin, Melissa P and Bona, Kira and Cain, Lucy and Dinofia, Amanda and Grupp, Stephen and Kelly, Colleen and Maude, Shannon and Myers, Regina and Parsons, Susan K and Rheingold, Susan R and Tasian, Sarah K and White, Claire and Zheng, Daniel J and Leahy, Allison Barz},
  title = {“Time is of the essence”: physician challenges impact patient access to chimeric antigen receptor T-cell therapy},
  journal = {JNCI Cancer Spectrum},
  year = {2026},
  doi = {10.1093/jncics/pkag123}
}
Kostenlos starten →